Factors Associated with Lymph Node Involvement in T1 cT1N0 HER2-Positive Breast Cancer
This study sought to determine the patient and tumor characteristics associated with positive lymph nodes status in T1 HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 6, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Analysis Reveals Ideal Time Period to Begin Adjuvant Chemotherapy for HER2-Positive Breast Cancer
The study found that 31 to 60 days seems to be the ideal time period to begin adjuvant chemotherapy in HER2-positive breast cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - March 6, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Individualizing Early-Stage HER2-Positive Breast Cancer
As more agents become approved, it ’s important to individualize therapy for this patient population, Sara A. Hurvitz, MD, said at the 37th Annual Miami Breast Cancer Conference. (Source: CancerNetwork)
Source: CancerNetwork - March 6, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA D.I.S.C.O.: Olaparib for gBRCAm HER2-negative metastatic breast cancer
FDA medical oncologists discuss the January 12, 2018, approval of olaparib, the first PARP inhibitor approved for the treatment of patients with metastatic breast cancer with a germline BRCA mutation. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 28, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA accepts Roche ’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) for the fixed-dose combination (FDC) of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC) injection in combination with intravenous (IV) chemotherapy, (Source: World Pharma News)
Source: World Pharma News - February 27, 2020 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
LOS ANGELES, Calif., Feb. 26, 2020 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for neratinib in combination... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 26, 2020 Category: Drugs & Pharmacology Source Type: news

FDA approves neratinib for metastatic HER2-positive breast cancer
Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 26, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves sNDA for Neratinib in Combination with Capecitabine for HER2+ Breast Cancer
The FDA approved a supplemental new drug application for neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received at least 2 prior anti-HER2-based regimens in the metastatic setting. (Source: CancerNetwork)
Source: CancerNetwork - February 26, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA accepts Roche ’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer
Basel, 25 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the fixed-dose combination (FDC) of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subc utaneous (SC) injection in combination with intravenous (IV) chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer. The BLA for the FDC is based on results from the phase III FeDeriCa study, which demonstrated non-inferior levels of Perjeta in the blood (phar...
Source: Roche Investor Update - February 25, 2020 Category: Pharmaceuticals Source Type: news

FDA accepts Roche ’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer
Basel, 25 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the fixed-dose combination (FDC) of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subc utaneous (SC) injection in combination with intravenous (IV) chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer. The BLA for the FDC is based on results from the phase III FeDeriCa study, which demonstrated non-inferior levels of Perjeta in the blood (phar...
Source: Roche Media News - February 25, 2020 Category: Pharmaceuticals Source Type: news

FDA Accepts BLA for Fixed-Dose Subcutaneous Combination in HER2-Positive Breast Cancer
The FDA accepted a biologics license application for the fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase, administered by subcutaneous injection in combination with IV chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - February 25, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA Accepts Genentech ’s Biologics License Application for Fixed-Dose Subcutaneous Combination of Perjeta And Herceptin For HER2-Positive Breast Cancer
South San Francisco, CA -- February 24, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 24, 2020 Category: Drugs & Pharmacology Source Type: news

FDA Grants 2 Fast Track Designations for ALX148
The FDA granted 2 Fast Track designations for ALX148 for the first-line treatment of patients with head and neck squamous cell carcinoma, and for the second-line treatment of patients with HER2-positive gastric or gastroesophageal junction carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - February 18, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA Grants Priority Review to Tucatinib for HER2-Positive Breast Cancer Treatment
The FDA granted a priority review to a new drug application submitted by Seattle Genetics, Inc. for tucatinib to treat patients with HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - February 14, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Seattle Genetics Announces FDA Filing Acceptance for Priority Review of Tucatinib New Drug Application (NDA) for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
BOTHELL, Wash.--(BUSINESS WIRE) February 13, 2020 -- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Company’s New Drug Application (NDA) for the... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 13, 2020 Category: Drugs & Pharmacology Source Type: news

High BMI May Cut Overall Survival in HER2 + Metastatic Breast Cancer
BMI had no impact on progression - free survival to first - line chemotherapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 12, 2020 Category: Cancer & Oncology Tags: Gynecology, Oncology, Journal, Source Type: news

High BMI May Cut Overall Survival in HER2 & #43; Metastatic Breast Cancer
WEDNESDAY, Feb. 12, 2020 -- For patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC) treated with pertuzumab and/or trastuzumab emtansine (T-DM1), a body mass index (BMI) of ≥30 kg/m² is... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 12, 2020 Category: Pharmaceuticals Source Type: news

Researchers uncover two-drug combo that halts the growth of cancer cells
(UT Southwestern Medical Center) UT Southwestern Simmons Cancer Center researchers have discovered a two-drug combo that halts the growth of cancer cells that carry HER2 mutations. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 23, 2020 Category: Cancer & Oncology Source Type: news

Breakthroughs in Metastatic Breast Cancer From SABCS 2019 Breakthroughs in Metastatic Breast Cancer From SABCS 2019
In metastatic breast cancer, top news at SABCS 2019 focused on two highly active drugs in HER2+ disease, an oral paclitaxel in TNBC, and evidence for a new standard front-line therapy in HR+ disease.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 8, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Africa: Hummingbird Bioscience Publishes Preclinical Data Demonstrating Efficacy of Hmbd-001 in Her3 Driven Cancers
[PR Newswire] Singapore -HER3 activation is implicated in tumor progression and in acquired resistance to EGFR and HER2 therapies (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - January 8, 2020 Category: African Health Source Type: news

T-DM1, Lapatinib, Nab-paclitaxel in HER2+ Breast Cancer T-DM1, Lapatinib, Nab-paclitaxel in HER2+ Breast Cancer
Should dual HER2 blockade plus nab-paclitaxel be considered for neoadjuvant treatment of HER2+ breast cancer?Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 7, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Early Breast Cancer Highlights From SABCS 2019 Early Breast Cancer Highlights From SABCS 2019
In early breast cancer, key points from SABCS include two major presentations in HER2+, benefit of preoperative pembrolizumab in TNBC, and CDK4/6 inhibition in the preoperative setting in HR+ disease.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 6, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Trastuzumab with Adjuvant Chemotherapy Reduces Risk of Relapse in HER2+ Breast Cancer
An analysis of the results of the phase III PANTHER trial showed that a combination of tailored dose-dense adjuvant chemotherapy and trastuzumab decreased the relative risk of relapse for patients with HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - January 3, 2020 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news

Drug Trials Snapshot: ENHERTU
Treatment of adults with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Used in patients who have been previously treated for their metastatic disease with at least two anti-HER2 regimens. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 2, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

' Huge Year' for HER2+ Breast Cancer: Incorporating New Treatments'Huge Year' for HER2+ Breast Cancer: Incorporating New Treatments
Drs Kathy Miller and Sara Hurvitz reflect on some of the trial results, including HER2CLIMB and DESTINY-Breast01, presented at this year's SABCS that may'take your breath away. 'Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 27, 2019 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Maryland biotech seeks FDA approval for breast cancer treatment
MacroGenics Inc. (NASDAQ: MGNX) is closing in on the finish line to earn regulatory approval for its first product, a breast cancer therapy candidate. The Rockville biotech has submitted its Biologics License Application to the Food and Drug Administration for margetuximab, which targets “HER2” — a gene that can fuel cancer cell growth. FDA approval would give MacroGenics the final go-ahead to commercialize the product and treat patients w ith metastatic HER2-positive breast cancer along with… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 26, 2019 Category: Biotechnology Authors: Sara Gilgore Source Type: news

MacroGenics seeks FDA approval for breast cancer treatment
MacroGenics Inc. (NASDAQ: MGNX) is closing in on the finish line to earn regulatory approval for its first product, a breast cancer therapy candidate. The Rockville biotech has submitted its Biologics License Application to the Food and Drug Administration for margetuximab, which targets “HER2” — a gene that can fuel cancer cell growth. FDA approval would give MacroGenics the final go-ahead to commercialize the product and treat patients w ith metastatic HER2-positive breast cancer along with… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 24, 2019 Category: Biotechnology Authors: Sara Gilgore Source Type: news

MacroGenics seeks FDA approval for breast cancer treatment
MacroGenics Inc. (NASDAQ: MGNX) is closing in on the finish line to earn regulatory approval for its first product, a breast cancer therapy candidate. The Rockville biotech has submitted its Biologics License Application to the Food and Drug Administration for margetuximab, which targets “HER2” — a gene that can fuel cancer cell growth. FDA approval would give MacroGenics the final go-ahead to commercialize the product and treat patients w ith metastatic HER2-positive breast cancer along with… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 24, 2019 Category: Pharmaceuticals Authors: Sara Gilgore Source Type: news

Zoledronic Acid and Neoadjuvant Chemo in HER2- Breast Cancer Zoledronic Acid and Neoadjuvant Chemo in HER2- Breast Cancer
While adjuvant bisphosphonates are associated with longer survival in postmenopausal women with breast cancer, the same cannot be said for neoadjuvant bisphosphonates.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 24, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Enhertu Approved for Unresectable, Metastatic HER2+ Breast Cancer
Title: Enhertu Approved for Unresectable, Metastatic HER2+ Breast CancerCategory: Health NewsCreated: 12/23/2019 12:00:00 AMLast Editorial Review: 12/24/2019 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - December 24, 2019 Category: Cancer & Oncology Source Type: news

Madelaine Kuiper, MSN, NP, Discusses Rapid Development of HER2-Targeted Therapies
The nurse practitioner from UCLA Health spoke about the expanding treatment options in this setting. (Source: CancerNetwork)
Source: CancerNetwork - December 24, 2019 Category: Cancer & Oncology Authors: Madelaine Kuiper, MSN, NP Source Type: news

Enhertu Approved for Unresectable, Metastatic HER2 + Breast Cancer
Treatment indicated for patients who have received at least two previous anti - HER2 - based regimens (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 24, 2019 Category: Cancer & Oncology Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news

Enhertu Approved for Unresectable, Metastatic HER2 & #43; Breast Cancer
MONDAY, Dec. 23, 2019 -- Enhertu (fam-trastuzumab deruxtecan-nxki) has received accelerated approval for treatment of unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer, the U.S. Food and Drug... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 23, 2019 Category: General Medicine Source Type: news

New Cancer Medication Offers Hope For HER2-Positive Patients Who Failed Other Treatments
Enhertu was approved for the treatment of adults with HER2-positive breast cancer, that was either unable to be removed with surgery, had already spread to other parts of the both, or to patients who had received two or more treatments specific to HER2-positive breast cancer. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 23, 2019 Category: Pharmaceuticals Authors: Dana Dovey, Contributor Source Type: news

Seattle Genetics Announces Submission of Tucatinib New Drug Application to the U.S. FDA for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
BOTHELL, Wash.--(BUSINESS WIRE) December 23, 2019 -- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced it has completed the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tucatinib. This NDA requests... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 23, 2019 Category: Drugs & Pharmacology Source Type: news

FDA OKs New Antibody Drug Conjugate for HER2+ Breast Cancer FDA OKs New Antibody Drug Conjugate for HER2+ Breast Cancer
Trastuzumab deruxtecan is for the treatment of unresectable or metastatic HER2-positive breast cancer that has received two or more prior anti-HER2-based regimens in the metastatic setting.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 21, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive breast cancer
The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (ENHERTU ®, Daiichi Sankyo) for patients with unresectable or metastatic HER2-positive breast cancer. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 20, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies
Today, the U.S. Food and Drug Administration granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. (Source: World Pharma News)
Source: World Pharma News - December 20, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA Approves Trastuzumab Deruxtecan for HER2-Positive Breast Cancer
The FDA granted accelerated approval to trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 20, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

FDA Approves Enhertu (fam-trastuzumab deruxtecan-nxki) for HER2-Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2 Based Regimens
20 December 2019 -- AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has approved Enhertu® (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 20, 2019 Category: Drugs & Pharmacology Source Type: news

European Commission approves Roche ’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
             Basel, 19 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Kadcyla ® (trastuzumab emtansine) for the adjuvant (after surgery) treatment of adult patients with HER2-positive early breast cancer (eBC) who have residual invasive disease in the breast and/or lymph nodes after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy.“Optimal treatment is vital for every patient with early-stage breast cancer, a setting where cures are possible,” said Levi Garraway, ...
Source: Roche Media News - December 19, 2019 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
Basel, 19 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Kadcyla ® (trastuzumab emtansine) for the adjuvant (after surgery) treatment of adult patients with HER2-positive early breast cancer (eBC) who have residual invasive disease in the breast and/or lymph nodes after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy.“Optimal treatment is vital for every patient with early-stage breast cancer, a setting where cures are possible,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product De...
Source: Roche Investor Update - December 19, 2019 Category: Pharmaceuticals Source Type: news

FDA Grants Breakthrough Therapy Designation for Tucatinib in HER2-Positive Breast Cancer
Seattle Genetics announced the development after data was presented at the 2019 San Antonio Breast Cancer Symposium. (Source: CancerNetwork)
Source: CancerNetwork - December 19, 2019 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Patrick I. Borgen, MD, Discusses Treatment Advances to Watch for in HER2-Positive Breast Cancer
The breast cancer expert discussed 2 advances in HER2-positive breast cancer treatment that healthcare providers should look for. (Source: CancerNetwork)
Source: CancerNetwork - December 19, 2019 Category: Cancer & Oncology Authors: Patrick I. Borgen, MD Source Type: news

Scientists make 'exciting' advancement in certain breast cancer drugs
Two new drug treatments for HER2-positive breast cancer were tested in separate studies. One study involves the drug Tucatinib, and the other involves an antibody-drug called trastuzumab deruxtecan. (Source: CNN.com - Health)
Source: CNN.com - Health - December 18, 2019 Category: Consumer Health News Source Type: news

Failed ATEMPT: T-DM1 No Safer in Early HER2+ Breast Cancer Failed ATEMPT: T-DM1 No Safer in Early HER2+ Breast Cancer
Trastuzumab emtansine showed no disease-free survival or safety advantage over paclitaxel + trastuzumab in the adjuvant setting for patients with stage 1 HER2-positive breast cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 12, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Foundation Medicine Expands Companion Diagnostics Offerings
FoundationOne CDx has earned yet another approval from FDA, making the companion diagnostic now available for 19 FDA-approved targeted therapies. It can now be used as a companion diagnostic for Piqray (alpelisib) in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. FDA approved Piqray in May 2019, and it is the first and only treatment specifically for patients with a PIK3CA mutation i...
Source: MDDI - December 12, 2019 Category: Medical Devices Authors: Daphne Allen Tags: IVD Source Type: news

Roche ’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer
Roche today announced new data from the phase III FeDeriCa study which showed the investigational fixed-dose combination (FDC) of Perjeta ® (pertuzumab) and Herceptin® (trastuzumab), administered by subcutaneous (SC) injection in combination with intravenous (IV) chemotherapy, demonstrated non-inferior levels of Perjeta in the blood (pharmacokinetics) and comparable efficacy and safety to standard IV infusions of Perjeta plus Hercep tin and chemotherapy in eligible people with HER2-positive early breast cancer (eBC). (Source: Roche Investor Update)
Source: Roche Investor Update - December 12, 2019 Category: Pharmaceuticals Source Type: news

Roche ’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer
Roche today announced new data from the phase III FeDeriCa study which showed the investigational fixed-dose combination (FDC) of Perjeta ® (pertuzumab) and Herceptin® (trastuzumab), administered by subcutaneous (SC) injection in combination with intravenous (IV) chemotherapy, demonstrated non-inferior levels of Perjeta in the blood (pharmacokinetics) and comparable efficacy and safety to standard IV infusions of Perjeta plus Hercep tin and chemotherapy in eligible people with HER2-positive early breast cancer (eBC). (Source: Roche Media News)
Source: Roche Media News - December 12, 2019 Category: Pharmaceuticals Source Type: news

SABCS: Addition of Tucatinib Ups Survival in HER2 + Metastatic Breast Cancer
In heavily pretreated patients, adding tucatinib versus placebo improves overall, progression - free survival (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 12, 2019 Category: Cancer & Oncology Tags: Gynecology, Neurology, Oncology, Pharmacy, Conference News, Source Type: news